BACKGROUND: A paraneoplastic syndrome is observed in 5% to 10% of cancer patients. Paraneoplastic vasculitis (PV) in metastatic renal cell carcinoma (mRCC) patients has been poorly investigated. AIMS: In our case series study, we evaluated the incidence and development of PV in patients with mRCC. METHODS AND RESULTS: Patients were required to have previously untreated clear-cell or papillary mRCC and no evidence of autoimmune diseases or venous thrombosis in history. Patients had a careful examination including Doppler ultrasonography of the blood vessels and skin punch biopsy in the presence of suspicious skin rash. Sixteen (8.2%) of 196 patients were diagnosed with PV, which was manifested clinically by leukocytoclastic vasculitis on the lower extremities. Skin biopsy confirmed vasculitis. Progression-free survival and overall survival were significantly better in patients without PV. CONCLUSIONS: PV is not rare paraneoplastic syndrome in mRCC. Leukocytoclastic vasculitis was the most common type of PV in this study.
BACKGROUND: A paraneoplastic syndrome is observed in 5% to 10% of cancerpatients. Paraneoplastic vasculitis (PV) in metastatic renal cell carcinoma (mRCC) patients has been poorly investigated. AIMS: In our case series study, we evaluated the incidence and development of PV in patients with mRCC. METHODS AND RESULTS:Patients were required to have previously untreated clear-cell or papillary mRCC and no evidence of autoimmune diseases or venous thrombosis in history. Patients had a careful examination including Doppler ultrasonography of the blood vessels and skin punch biopsy in the presence of suspicious skin rash. Sixteen (8.2%) of 196 patients were diagnosed with PV, which was manifested clinically by leukocytoclastic vasculitis on the lower extremities. Skin biopsy confirmed vasculitis. Progression-free survival and overall survival were significantly better in patients without PV. CONCLUSIONS: PV is not rare paraneoplastic syndrome in mRCC. Leukocytoclastic vasculitis was the most common type of PV in this study.
Authors: Nicolas A Giraldo; Etienne Becht; Yann Vano; Florent Petitprez; Laetitia Lacroix; Pierre Validire; Rafael Sanchez-Salas; Alexandre Ingels; Stephane Oudard; Audrey Moatti; Benedicte Buttard; Sarah Bourass; Claire Germain; Xavier Cathelineau; Wolf H Fridman; Catherine Sautès-Fridman Journal: Clin Cancer Res Date: 2017-02-17 Impact factor: 12.531
Authors: Pavel I Novikov; Sergey V Moiseev; Ekaterina I Kuznetsova; Eugenia N Semenkova; Nikolay A Mukhin Journal: Rheumatol Int Date: 2014-10-26 Impact factor: 2.631
Authors: Laura Burgess; Marissa Keenan; Alan Liang Zhou; Kiefer Lypka; Delvina Hasimja Saraqini; Jeff Yao; Samuel Martin; Christopher Morash; James Watterson; Christina Canil; Robert MacRae Journal: Curr Oncol Date: 2021-05-07 Impact factor: 3.677